A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 420 participants.
Also called NCT02773368
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 420 participants
- Sponsor
- Registry
-
NCT02773368 -
2015-001596-48
-
- Other papers using this trial's data
- Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Canada, Finland, Hungary, India, Russia, Slovakia, Slovenia, Spain, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT02773368. Randomized; no masking; primary purpose treatment. Start 2016-05-23 (actual); primary completion 2017-09-26 (actual). Results posted on 2018-10-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus
- Acronym
- DUALTM IX
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Intervention (Drug)
- insulin glargine
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02773368- Content hash
b3e10507252363e978cf28efbae67c006986a98c1b8af00ad331ced7ded69fb1